SELLAS Life Sciences Group (SLS) AI Stock Analysis

• Market Cap: $854.81M
• Dividend Yield: N/A
• Average Volume (3M): 7.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: N/A
• EPS Growth: 59.04%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 179,582,580
• 10 Day Avg. Volume: 4,870,487
• 30 Day Avg. Volume: 7,124,036
• PEG Ratio: 0.31
• Price to Book (P/B): 5.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -14.48
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -29.43
• 1Y Price Target: $10.00
• Price Target Upside: 143.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.32
• Revenue Forecast (FY): $36.13M

• Rating: 49 Neutral
• Price Target: $4.00 ▼(-2.68% Downside)
• Action: Reiterated Date: 03/21/26
• Date: Action: Reiterated 03/21/26

The score is primarily held down by weak financial performance, marked by ongoing losses, zero recent revenue, and sustained negative cash flow. Technicals are modestly supportive over the longer term but lack strong near-term momentum. Corporate events improve liquidity via warrant-exercise proceeds, partially offset by dilution risk, while valuation remains constrained by negative earnings.

Positive Factors

Improved liquidity from warrant exercises

The $42.6M of warrant proceeds materially extends the company’s runway and reduces immediate refinancing pressure, allowing continuing clinical development across programs. For a clinical-stage biotech, secured near-term capital materially lowers the likelihood of trial disruptions from funding gaps over the next several quarters.

Negative Factors

Persistent negative cash flow

Sustained negative operating and free cash flow forces repeated reliance on external financing to fund trials and operations. Even with recent improvement in burn, continued cash deficits increase dilution risk and create execution risk if capital markets tighten, making long-term program continuity contingent on financing outcomes.

SELLAS Life Sciences Group Business Overview & Revenue Model

Company Description

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer ...

Read more

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer ...

How the Company Makes Money

null...

SELLAS Life Sciences Group Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	1.00M	7.60M
Gross Profit	0.00	0.00	0.00	900.00K	7.40M
EBITDA	-28.27M	632.00K	529.00K	-31.49M	-18.32M
Net Income	-26.86M	-30.88M	-37.34M	-41.30M	-20.70M
Balance Sheet
Total Assets	78.34M	19.43M	6.22M	20.94M	26.43M
Cash, Cash Equivalents and Short-Term Investments	71.89M	13.89M	2.53M	17.13M	21.45M
Total Debt	1.00M	1.00M	906.00K	945.00K	808.00K
Total Liabilities	7.47M	9.97M	14.20M	16.09M	6.08M
Stockholders Equity	70.87M	9.46M	-7.98M	4.85M	20.35M
Cash Flow
Free Cash Flow	-28.39M	-35.40M	-36.91M	-28.31M	-26.02M
Operating Cash Flow	-28.39M	-35.40M	-31.41M	-23.81M	-26.02M
Investing Cash Flow	0.00	0.00	-5.50M	-4.50M	0.00
Financing Cash Flow	86.30M	46.76M	22.32M	24.08M	12.07M

SELLAS Life Sciences Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLS, the sentiment is Positive. The current price of 4.11 is below the 20-day moving average (MA) of 4.80, below the 50-day MA of 4.59, and above the 200-day MA of 2.76, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 50.50 is Neutral, neither overbought nor oversold. The STOCH value of 74.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLS.

SELLAS Life Sciences Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DMAC	54 Neutral	$322.76M	-11.41	-77.62%	―	―	-29.73%
BDTX	52 Neutral	$146.66M	6.18	17.46%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SLS	49 Neutral	$854.81M	-18.84	-63.06%	―	―	59.04%
VYGR	47 Neutral	$222.90M	-1.93	-51.35%	―	-80.88%	-388.61%
GALT	43 Neutral	$151.40M	-8.62	25.65%	―	―	18.82%

SELLAS Life Sciences Group Corporate Events